Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

T HEMANTH RAO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023070745
CMS profile
677428
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$0.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $0.83 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Travere Therapeutics, Inc. $0.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

T HEMANTH RAO

NPI 1023070745 · CMS profile ID 677428

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $0.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Travere Therapeutics, Inc. $0.8301/02/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960079589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5.57 2
PY2022 $0.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $590,566.02 42
PY2024 Principal investigator $757,803.02 58
PY2023 Principal investigator $705,507.39 95
PY2022 Recipient $3,120.00 1
PY2022 Principal investigator $783,014.66 39
PY2021 Principal investigator $424,194.70 79
PY2020 Principal investigator $514,521.07 71
PY2019 Principal investigator $249,052.37 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $20,785.00 12/22/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151469
Principal investigator 1 Roche Products Limited $4,245.00 12/22/2020 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 857148367
Principal investigator 1 F. Hoffmann-La Roche AG $2,958.00 12/15/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151463
Principal investigator 1 SK Life Science, Inc. $1,355.20 12/15/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
045569 No dispute reported 06/30/2026 733075637
Principal investigator 1 Novartis Pharmaceuticals Corporation $83,000.04 11/28/2020 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 753932704
Principal investigator 1 Roche Products Limited $6.55 11/24/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151539
Principal investigator 1 Roche Products Limited $26.69 11/24/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151545
Principal investigator 1 Roche Products Limited $17.75 11/24/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151549
Principal investigator 1 Roche Products Limited $57.00 11/24/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151555
Principal investigator 1 Roche Products Limited $1,850.00 11/02/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167989
Principal investigator 1 Roche Products Limited $1,400.00 10/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167967
Principal investigator 1 Roche Products Limited $4,972.51 10/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167979
Principal investigator 1 H. Lundbeck A S $653.75 10/22/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy No dispute reported 06/30/2026 747612623
Principal investigator 1 F. Hoffmann-La Roche AG $1,150.00 10/13/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151459
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $700.00 10/05/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167947
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,750.00 10/05/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167959
Principal investigator 1 F. Hoffmann-La Roche AG $8,861.00 09/24/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151455
Principal investigator 1 H. Lundbeck A S $685.00 09/23/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy No dispute reported 06/30/2026 747612525
Principal investigator 1 Roche Products Limited $1,119.00 09/22/2020 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 857148363
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $700.00 09/01/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167935
Principal investigator 1 H. Lundbeck A S $2,675.00 08/26/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy No dispute reported 06/30/2026 747612377
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $6,637.51 08/17/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167923
Principal investigator 1 SK Life Science, Inc. $1,072.80 08/07/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
45569 No dispute reported 06/30/2026 733075613
Principal investigator 1 Biogen, Inc. $86.00 08/03/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE - PHARMACY
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) No dispute reported 06/30/2026 736755283
Principal investigator 1 H. Lundbeck A S $1,876.25 07/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy No dispute reported 06/30/2026 747612205
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $700.00 07/23/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167913
Principal investigator 1 SK Life Science, Inc. $4,283.40 07/17/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
45569 No dispute reported 06/30/2026 733075617
Principal investigator 1 F. Hoffmann-La Roche AG $24,395.00 07/02/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151449
Principal investigator 1 Roche Products Limited $6,927.00 07/02/2020 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 857148359
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $700.00 06/18/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167905
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.28 06/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151525
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.28 06/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151531
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $173.46 06/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151535
Principal investigator 1 UCB SA $3,201.30 06/04/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753373923
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,400.00 05/26/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167883
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,400.00 05/26/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167891
Principal investigator 1 F. Hoffmann-La Roche AG $1,437.50 05/26/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151445
Principal investigator 1 UCB SA $64,026.50 04/30/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753373053
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.28 04/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151505
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.28 04/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151511
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3.50 04/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151515
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $9.76 04/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151521
Principal investigator 1 UCB SA $9,200.00 04/20/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 753373609
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,394.15 04/16/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167869
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4.36 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151473
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.17 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151477
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $17.74 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151481
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $11.75 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151487
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $19.40 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151491
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $0.30 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151497
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $57.00 04/14/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 857151501
Principal investigator 1 F. Hoffmann-La Roche AG $8,861.00 04/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 857151439
Principal investigator 1 Roche Products Limited $1,119.00 04/09/2020 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 857148353
Principal investigator 1 UCB SA $139,744.50 04/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 753374775
Principal investigator 1 UCB SA $21,442.90 03/23/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 753373133
Principal investigator 1 UCB SA $58.36 03/06/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753373757
Principal investigator 1 UCB SA $8.52 03/06/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753375153
Principal investigator 1 UCB SA $418.78 03/05/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 753373155
Principal investigator 1 SK Life Science, Inc. $772.20 02/21/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension No dispute reported 06/30/2026 733075565
Principal investigator 1 UCB SA $12.85 02/19/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753373399
Principal investigator 1 GRT US Holding, Inc. $1,000.00 02/13/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
KF7013-02 No dispute reported 06/30/2026 745988505
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,400.00 02/03/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167857
Principal investigator 1 UCB SA $3,650.09 01/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 753373367
Principal investigator 1 UCB SA $1,284.20 01/29/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 753374155
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $8,280.01 01/27/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD No dispute reported 06/30/2026 743167845
Principal investigator 1 UCB SA $10,097.10 01/27/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 753373287
Principal investigator 1 UCB SA $13,558.50 01/27/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 753375021
Principal investigator 1 SK Life Science, Inc. $1,343.10 01/21/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension No dispute reported 06/30/2026 733075559
Principal investigator 1 UCB SA $16,848.10 01/21/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATOR No dispute reported 06/30/2026 753373785
Principal investigator 1 GRT US Holding, Inc. $156.40 01/09/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
KF7013-02 No dispute reported 06/30/2026 745988497
Principal investigator 1 F. Hoffmann-La Roche AG $11,377.00 01/02/2020 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 743167829